1	Title: SARS-CoV-2 subgenomic RNA kinetics in longitudinal clinical samples
2	
3	Authors:
4	Renu Verma <sup>1</sup> , Eugene Kim <sup>1</sup> , Giovanny Joel Martinez-Colón <sup>1</sup> , Prasanna Jagannathan <sup>1</sup> , Arjun
5	Rustagi <sup>1</sup> , Julie Parsonnet <sup>1,2</sup> , Hector Bonilla, <sup>1</sup> Chaitan Khosla <sup>3</sup> , Marisa Holubar, <sup>1</sup> Aruna
6	Subramanian, <sup>1</sup> Upinder Singh <sup>1</sup> , Yvonne Maldonado <sup>4</sup> , Catherine A. Blish, <sup>1</sup> Jason R. Andrews <sup>1</sup>
7	1. Division of Infectious Diseases and Geographic Medicine, Stanford University School of
8	Medicine, Stanford, CA, USA
9	2. Department of Epidemiology and Population Health Stanford University School of
10	Medicine, Stanford, CA, USA
11	3. Departments of Chemistry and Chemical Engineering, Stanford University, Stanford,
12	California 94305, United States
13	4. Department of Pediatrics, Stanford University School of Medicine, Stanford, California
14	
15	Keywords: COVID-19, infectiousness, SARS-CoV-2, subgenomic RNA, cohort
16	
17 18	Abstract Word Count: 267 Word Count: 3086
19	<b>Running title:</b> sgRNA kinetics in COVID-19 patients
20	
21	Correspondence:
22	Jason Andrews
23	Division of Infectious Diseases and Geographic Medicine
24	Stanford University School of Medicine
25	Biomedical Innovations Building, Rm 3458
26 27	240 Pasteur Dr. Stonford, CA 94305
27 28	Stanford, CA 94305 Email: jandr@stanford.edu
28	Phone: +1 650 497 2679

- 32 **Summary:** We observed prolonged detection of subgenomic RNA in nasal swabs and equivalent 33 decay rates to genomic RNA in both longitudinal nasal swabs and in remdesivir-treated 34 A549<sup>ACE2+</sup> cells infected with SARS-CoV-2. Taken together, these findings suggest that 35 subgenomic RNA from SARS-CoV-2 is comparably stable to genomic RNA and that its
- 36 detection is therefore not a more reliable indicator of replicating virus.

#### 38 Abstract

#### 39 Background

Given the persistence of viral RNA in clinically recovered COVID-19 patients, subgenomic
RNAs (sgRNA) have been reported as potential molecular viability markers for SARS-CoV-2.

- 42 However, few data are available on their longitudinal kinetics, compared with genomic RNA
- 43 (gRNA), in clinical samples.

#### 44 Methods

We analyzed 536 samples from 205 patients with COVID-19 from placebo-controlled, outpatient trials of Peginterferon Lambda-1a (Lambda; n=177) and favipiravir (n=359). Nasal swabs were collected at three time points in the Lambda (Day 1, 4 and 6) and favipiravir (Day 1, 5, and 10) trials. N-gene gRNA and sgRNA were quantified by RT-qPCR. To investigate the decay kinetics *in vitro*, we measured gRNA and sgRNA in A549<sup>ACE2+</sup> cells infected with SARS-CoV-2, following treatment with remdesivir or DMSO control.

51 **Results** 

52 At six days in the Lambda trial and ten days in the favipiravir trial, sgRNA remained detectable 53 in 51.6% (32/62) and 49.5% (51/106) of the samples, respectively. Cycle threshold (Ct) values 54 for gRNA and sgRNA were highly linearly correlated (Pearson's r=0.87) and the rate of increase 55 did not differ significantly in Lambda (1.36 cycles/day vs 1.36 cycles/day; p = 0.97) or 56 favipiravir (1.03 cycles/day vs 0.94 cycles/day; p=0.26) trials. From samples collected 15-21 57 days after symptom onset, sgRNA was detectable in 48.1% (40/83) of participants. In SARS-CoV-2 infected A549<sup>ACE2+</sup> cells treated with remdesivir, the rate of Ct increase did not differ 58 59 between gRNA and sgRNA.

60 Conclusions

- 61 In clinical samples and *in vitro*, sgRNA was highly correlated with gRNA and did not
- 62 demonstrate different decay patterns to support its application as a viability marker.

63

#### 65 **INTRODUCTION**

66 Understanding and quantifying the replicating or transcriptionally active virus among individuals 67 with SARS-CoV-2 could inform treatment decisions and response monitoring, as well as the 68 need for isolation, contact tracing and infection control measures. The duration of infectiousness 69 as estimated from transmission studies appears much shorter than the duration of PCR positivity 70 in airway secretions (1,2). Studies comparing culture and RT-PCR from the same samples have 71 revealed that there is often substantial discrepancy between these measurements, with PCR 72 remaining positive for days to weeks longer than culture (3-7). While culture remains the 73 reference standard for detection of infectious virus, it may lack sensitivity, and it requires 74 biosafety level 3 facilities, precluding its use at scale as a clinical or public health tool (8). To 75 overcome this obstacle, there has been considerable interest in the development of molecular 76 viability markers to sensitively detect and quantify transcriptionally active virus (3,9,10).

77

78 SARS-CoV-2 is an enveloped, positive sense, single-stranded RNA virus which employs a 79 complicated pattern of replication as well as transcription of genome length and smaller sgRNAs 80 (11). These sgRNAs are transcriptional intermediates, susceptible to enzymatic degradation, and 81 are not believed to be packaged in the final progeny virion, making them an attractive marker for 82 an actively transcribing virus (12). Small clinical studies have suggested that, compared with 83 gRNA, sgRNA correlates better with culturable virus. These studies targeted N-gene to detect 84 gRNA and compared sgRNA stability with a relatively less abundant/sensitive E-gene sgRNA 85 assay (2,3,9). Despite the E-gene sgRNA assay possibly being suboptimal and may give false 86 negative results, these findings have led to the use of sgRNA assay as an outcome in preclinical 87 investigation of novel therapies (13,14) and its suggested use to terminate medical isolation for

88 individuals with COVID-19 (3). In contrast, a recent study found that sgRNAs were detectable 89 up to 17 days after initial detection and that they may be protected from nuclease degradation by 90 double membrane vesicles (15). However, because this study only had 12 clinical samples, 91 further evidence about the kinetics of sgRNA versus gRNA in longitudinal samples is needed to 92 determine whether sgRNA abundance better reflects recently transcribing viral infection. 93 Additionally, in order to serve as a marker of replicating virus, sgRNA is expected to show a 94 rapid decline after transcriptional inhibition due to ribonuclease degradation, in contrast to 95 gRNA, which may be protected from degradation by viral capsids and therefore persist more 96 durably (16). Therefore, we hypothesized that, upon treatment with SARS-CoV-2 RNA-97 dependent RNA polymerase inhibitors (17, 18, 19) in cell lines infected with SARS-CoV-2, we 98 should observe a rapid decline of sgRNA after viral death when compared with gRNA.

99

100 To address these gaps, we developed an N-gene sgRNA assay to directly compare its stability 101 with N-gene gRNA. sgRNAs in SARS-CoV-2 share a common leader sequence at the 5' end 102 which is absent in the gene amplified from the gRNA (9). We combined the common leader 103 sequence as forward primer with CDC N1 gene assay's reverse primer (20) to facilitate 104 comparison of N-gene sgRNA with gRNA copies. We applied this assay to serial samples from 105 individuals participating in two randomized clinical trials to characterize decay rates. 106 Additionally, we leveraged the inhibition of viral transcription and replication by an RNA-107 dependent RNA polymerase inhibitor (remdesivir) (19) to measure and compare the decay 108 kinetics of gRNA and sgRNA following polymerase inhibition in SARS-CoV-2 infected A549<sup>ACE2+</sup> cells. 109

#### 111 METHODS

112

#### 113 **Ethics statement**

114 All participants were >18 years of age and provided written informed consent. The studies were

approved by the Stanford IRB (#57686 and #58869).

116

#### 117 Overview and Study Population

118 This was a sub-study of two Phase 2 randomized, placebo-controlled trials of peginterferon-119 Lambda-1a (Lambda) (NCT04331899) and favipiravir (NCT04346628) for treatment of 120 COVID-19. Individuals >18 years of age with RT-PCR confirmed SARS-CoV-2 infection were 121 recruited to participate and were eligible if they could be randomized within 72 hours of a 122 positive SARS-CoV-2 test and were not hospitalized. Additional exclusion criteria were 123 respiratory rate < 20 breaths per minute, room air oxygen saturation <94%, pregnancy or 124 breastfeeding, or use of other investigational agents for treatment of COVID-19. In the Lambda 125 trial, enrolled participants were randomized to a single injection with 180 mcg of Lambda versus 126 placebo injection and followed for 28 days. In the favipiravir trial, individuals were randomized 127 to oral favipiravir tablets (1800 mg on day 1, followed by 800 mg twice daily for 9 days) or 128 matching placebo. The primary outcome for both studies was time to cessation of viral shedding 129 as measured by qRT-PCR performed on oropharyngeal swab samples (Lambda trial) or nasal 130 swabs (favipiravir trial). In August 2020, we amended both protocols to collect nasal swabs (LH-131 11-10 Longhorn Hydra Sterile Flocked Swab) to assay for gRNA and sgRNA. For Lambda trial, 132 it was earlier found that in both patients receiving Lambda and placebo, the median time to 133 cessation of viral shedding was 7 days (21). A single dose of subcutaneous Peginterferon

Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved
symptoms in outpatients (21). The favipiravir trial is an ongoing study and remains blinded.

136

#### 137 RNA extraction and quantitative RT-PCR assay for SARS-CoV-2 RNA

138 Nasal swabs were collected and transported in 500 ul of Primestore MTM (Longhorn Vaccines 139 & Diagnostics) RNA stabilizing media. RNA was extracted using MagMAX<sup>TM</sup> Viral/Pathogen 140 Ultra Nucleic Acid Isolation Kit (Cat # A42356 Applied Biosystems) according to the 141 manufacturer's instructions and eluted in 50ul of elution buffer. We performed qRT-PCR for the 142 N gene using the CDC qualified primers and probes amplifying N1 region of SARS-CoV-2 N-143 gene (20). TaqPath one-step RT-PCR mastermix (Invitrogen, Darmstadt, Germany) was used in 144 a 20ul reaction volume and the samples were analyzed on a StepOne-Plus (Applied Biosystems) 145 instrument, using the following program: 10 min at 50 °C for reverse transcription, followed by 3 146 min at 95 °C and 40 cycles of 10 s at 95 °C, 15 s at 56 °C, and 5 s at 72 °C. We estimated 147 copies/sample from a standard curve using a pET21b+ plasmid (GenScript, USA) with the N-148 gene. The cycle threshold (Ct) cutoff for positive samples was <38.

149

#### 150 Quantitative RT-PCR Assay for SARS-CoV-2 sgRNA

Since all sgRNAs are known to carry a common leader sequence, to amplify N-gene sgRNA, we combined a previously described E-gene sgRNA forward primer for SARS-CoV-2 leader sequence along with the CDC N1-gene segment reverse primer and probe to detect N-gene sgRNA (3). We used TaqPath one-step RT-PCR mastermix with 400 nM concentrations of each of the primer and 200 nM of probe to amplify sgRNA. The N-gene PCR reactions conditions were used for sgRNA amplification. We estimated copies/sample from a standard curve using a

pET21b+ plasmid with the N-gene sgRNA sequence. The cycle threshold (Ct) cutoff for positive
samples was <38.</li>

159

#### 160 sgRNA validation by Sanger sequencing

For the first 15 positive clinical samples, we confirmed amplification product identity by Sanger sequencing. We performed endpoint PCR using the same primers, purified it by gel electrophoresis, and performed Sanger sequencing with these primers. The resulting sequences were aligned using to SARS-CoV-2 genome (GenBank: MT568638.1) to compare sequence similarity of the product with the leader sequence and N-gene. Samples were considered positive for sgRNA if the leader sequence identity with the reference genome was greater than 98%.

167

#### 168 sgRNA kinetics in SARS-CoV-2 infected A549<sup>ACE2+</sup> cells

#### 169 *Cell culture and in vitro SARS-CoV-2 infection:*

170 The human lung epithelial carcinoma cell line, A549, overexpressing Angiotensin-converting enzyme 2 (ACE2), A549<sup>ACE2+</sup>, was provided by Ralf Bartenschlager (Heidelberg University) 171 (22). A549<sup>ACE2+</sup> cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Life 172 173 technologies; 11885-092) supplemented with 10% Fetal bovine serum (Corning; MT35016CV), 174 1% Penicillin-Streptomycin (Thermo Fisher Scientific; 15070063), and 623ug/ml of Geneticin 175 (Thermo Fisher Scientific; 10121035). For viral infection, cells were seeded a day before infection by culturing 1x10<sup>5</sup> cells per well in a 6-well plate (Corning). Cells were at passage 14 176 177 at the time of infection. Viral infection was performed with the Washington strain of SARS-178 CoV-2 (2019-nCOV/USA-WA1/2020), titered by plaque assay on VeroE6 cells, at a multiplicity 179 of infection (MOI) of 1. Briefly, in Biosafety level 3 (BSL3) containment, culture media was

180 removed, and cells were washed with phosphate buffered saline (PBS) (Thermo Fisher 181 Scientific; 10-296-028) multiple times before adding the viral stock. Cells were then incubated at 182 37°C with 5% CO<sub>2</sub> for 1 hour while gently rocking. After 1 hour, cells were washed with 1x PBS 183 and incubated in culture media. Supernatant and cells were collected at 1 and 24 hours post-184 infection (hpi) in TRIzol LS (Thermo Fisher Scientific; 10010023) for RNA extraction. Other 185 wells were either treated with 0.1% final concentration of dimethylsulfoxide (DMSO) (Sigma 186 Life Science: Cat# D2650) or 10µM remdesivir (Gilead, Cat# NDC 61958-2901-2) in 0.1% 187 DMSO and cultured for longer periods (48, 72, and 96hpi). It has been previously demonstrated that at 10µM prodrug concentration, remdesivir potently inhibits SARS-CoV-2 in A549<sup>ACE2+</sup> 188 cells (23). Cytopathic effect on SARS-CoV-2 in vitro-infected A549<sup>ACE2+</sup> cells that were treated 189 190 with either 10µM remdesivir or vehicle, 0.1% DMSO, was monitored before and after infection. 191 Cell line experiments at all time-points and treatment conditions were performed in technical 192 duplicates. Cells and supernatant were collected, and RNA was extracted independently for all 193 technical duplicates without pooling. An image of cells was collected using an EVOS XL core 194 imaging system (Thermo Fisher scientific), with a 10x objective, before collecting cell pellet and 195 supernatant from each treatment, and time point.

196

197 RNA extraction and RT-PCR

198 RNA from supernatant and cells collected at 1, 24, 48, 72 and 96 hpi in TRIzol LS was extracted 199 using isolated using standard phenol-chloroform extraction per manufacturer's instructions. The 200 SARS-CoV-2 genomic and sgRNA RT-qPCR assays from cell line technical duplicates were 201 further performed in technical duplicates. The RNA copies were quantified using standard curves derived from plasmids. Eukaryotic 18S rRNA commercial TaqMan assay (4333760T, Thermo
Fisher Scientific) was used as an internal control.

204

#### 205 Statistical Analyses

We estimated the change in cycle threshold (Ct) value for gRNA and sgRNA by day using generalized linear mixed models with random effect for participant. We tested for differences in the coefficients for collection day for outcomes of gRNA and sgRNA by performing ANOVA on a joint model with a dummy variable for RNA type. We used generalized additive mixed models with a random effect for participant to investigate the relationship between sample collection day and cycle threshold (Ct) values. All analyses were performed using R (24).

212

#### 213 **RESULTS**

#### 214 Study population characteristics

215 We recruited 205 COVID-19 positive patients from placebo-controlled trials of interferon 216 Lambda (n=66) and Favipiravir (n=139) between August, 2020 and January, 2021. All 217 participants were enrolled in the trials within 72 hours of a positive SARS-CoV-2 RT-qPCR test. 218 Median age of the participants was 40 years (range, 18-73), and 46.8% (96/205) were female. 219 The majority of participants (197/205; 96.1%) reported one or more COVID-19 related 220 symptoms several days prior to enrollment (median, 5 days; range, 0-21). Symptoms with onset 221 more than three weeks prior to study enrollment were not considered to be associated with 222 COVID-19. The most common baseline symptoms reported by the patients before randomization 223 were cough, diarrhea, body ache, headache, fatigue and shortness of breath (Table 1).

#### 225 gRNA and sgRNA RT-qPCR positivity in clinical samples

226 We analyzed 536 nasal swab samples collected from 205 COVID-19 patients from the Lambda 227 (n=177) and favipiravir (n=359) trials between 0 to 21 days post symptom onset. For the 228 favipiravir trial, nasal swabs were collected on the day of enrollment (day 1), followed by day 5 229 and day 10. For Lambda trial, nasal swabs were collected on the day of enrollment (day 1) 230 followed by day 4 and day 6. Overall gRNA RT-qPCR positivity in samples from the favipiravir 231 trial on day 1, 5 and 10 was 91.5%, 82.9% and 60.3% respectively (Table 2). For sgRNA, 232 positivity was 89.2%, 77.2% and 49.5%. For the Lambda trial, overall gRNA positivity on day 1, 233 4 and 6 was 91.6%, 90.9% and 91.9% respectively. For sgRNA, overall positivity was 81.6%, 234 74.5% and 51.6%. We observed a high correlation (Pearson's r = 0.87) between the cycle 235 threshold (Ct) values of gRNA and sgRNA at all time points, and detection of sgRNA was 236 strongly predicted by gRNA Ct (Figure 1). For the first 15 samples for which sgRNA showed 237 positive amplification, we performed Sanger sequencing. All fifteen samples had more than 98% 238 identity with SARS-CoV-2 leader sequence, confirming amplification of the sgRNA transcript 239 (Supplementary figure 1). In a subset of 35 samples in which we performed testing for E-gene 240 sgRNA using a previously published assay, we found high correlation (Pearson's r=0.89) with 241 N-gene sgRNA, but with higher Ct values (median difference, 4.1 cycles) among positive 242 samples. Among 35 samples positive for N-gene sgRNA, 69.0% (24/35) were negative for E-243 gene sgRNA (Supplementary figure 2).

244

245 Randomization data was available for the Lambda study while favipiravir still remains blinded.

246 We did not observe any significant difference in the Ct values of sgRNA between Lambda and

247 placebo recipients. At day six, the gRNA percentage positivity was 83.8% (26/31) (median Ct

248	value = 32.5) in Lambda and 100% (31/31) (median Ct value =33.4) in placebo arm. In sgRNA
249	at day six, percentage positivity was 48.3% (15/31) (median Ct value = 38.0) in Lambda and
250	54.8% (17/31) (median Ct value =35.9) in placebo arm (p=0.903).

251

We found no difference in the rate of Ct value increase by day in gRNA compared with sgRNA in the Lambda (1.36 cycles/day vs 1.36 cycles/day; p=0.97) or favipiravir (1.03 cycles/day vs 0.94 cycles/day; p=0.26) trials (Figure 2). Among samples collected 15-21 days after symptom onset from both trials combined, sgRNA was detectable in 48.1% (40/83) of participants (Figure 3).

257

### 258 sgRNA kinetics in SARS-CoV-2 infected A549<sup>ACE2+</sup> cells treated with remdesivir

259 We compared SARS-CoV-2 gRNA and sgRNA degradation kinetics after transcriptional inhibition by antiviral drug remdesivir. We treated SARS-CoV-2 infected A549<sup>ACE2+</sup> cells with 260 261 0.1% DMSO vehicle control and 10µM remdesivir at 24hpi. Cytopathic effects were observed in 262 cells treated with DMSO control but not remdesivir (Supplementary figure 3). Compared with 263 DMSO treated cells, SARS-CoV-2 replication in remdesivir treated cells was markedly reduced 264 (nadir gRNA Ct 9.6 vs 14.2; nadir sgRNA Ct 10.0 vs 14.5). In remdesivir-treated cells, gRNA 265 and sgRNA Ct values rose at similar rates in cells (0.11/hour vs 0.09/hour; p=0.153) and 266 declined by similar rates in supernatant (-0.06/hour vs 0.06/hour; p=0.914) (Figure 4).

267

#### 269 **DISCUSSION**

270 While there has been considerable interest in the use of sgRNAs as markers of replicating SARS-271 CoV-2 infection, evidence concerning the decay of sgRNA following onset of infection in 272 humans and cell culture has been lacking. Using longitudinal samples from two clinical trials, we 273 found that sgRNA was detectable in 46% of participants from the Lambda trial and 50% from 274 favipiravir trial 15-21 days after symptoms onset. While gRNA was detectable for longer than 275 sgRNA, they were highly correlated and had indistinguishable rates of decline within individuals 276 over time. We found consistent results in cell culture, whereby gRNA and sgRNA copies 277 declined at the same rate following inhibition of transcription by remdesivir. Taken together, 278 these findings suggest that detection of sgRNAs is not a reliable marker of recent viral 279 transcription and does not provide marginal information over quantification of gRNA. Earlier 280 findings of greater specificity of sgRNAs than gRNAs compared with a reference standard of 281 culture may be explained by the lower analytical sensitivity of the sgRNA assays (3,9,10), 282 particularly using less sensitive E-gene assays.

283

284 RNA transcripts have been used as markers of viability or metabolic activity for a number of 285 bacterial and viral pathogens. In bacteria, mRNAs have much shorter half-lives than DNA due to 286 degradation by ribonucleases, such that their presence indicates recent metabolic activity 287 (25,26,27). Similarly, RNA transcription assays have been used to assess replication competent 288 viral pool size for HIV-1 (28). For SARS-CoV-2, sgRNA transcription is believed to occur 289 inside double membrane vesicles, which may protect viral genomic and subgenomic RNA from 290 cytoplasmic degradation due to host enzymes (29-33). We found that sgRNA and gRNA 291 increased at the same rate following infection of cells and then declined at the same rate

following cell death (in the control cells treated with DMSO) or following inhibition of RDRP (RNA dependent RNA polymerase) by remdesivir. If sgRNAs were rapidly degraded by ribonucleases, we would have expected a more rapid decline in sgRNAs compared with gRNAs, but this was not observed. Similarly, in the supernatant, we saw no difference in change in sgRNAs compared with gRNAs, again failing to identify rapid clearance of sgRNAs by ribonucleases.

298

299 Several previous studies have targeted E-gene sgRNA, reporting in small clinical series that 300 these correlated well with culture (34, 35). This finding may be explained by the fact that E-gene 301 transcripts are less abundant than N-gene transcripts, so assays targeting them will have lower 302 analytical sensitivity (36). Indeed, we performed direct comparison of N-gene and E-gene assays 303 and found that the latter were approximately 5 Ct values higher for the same sample. There is not 304 clear premise to infer that E-gene transcripts are more rapidly degraded by ribonucleases or that 305 they better reflect recent transcription than N-gene sgRNAs. Negative-strand RNA detection in 306 SARS-CoV-2 has recently been reported as another potential viability marker (37). In a study by 307 Alexanderson and group, negative strand RNA was detected up to 11 days (15). However, 308 negative strand assays may be less analytically sensitive than sgRNA assays (37). This could 309 make them appear to be more specific, compared with culture, in clinical samples as they are 310 more likely to be negative when viral abundance is low.

311

312 Our study has several limitations, which include lack of viral culture data and samples at later 313 timepoints. Additionally, to study the sgRNA decay kinetics, we targeted a single and highly 314 abundant gene to compare and quantify gRNA and sgRNA, though we found high correlation

between E-gene and N-gene sgRNA copy numbers. Analyzing additional targets would help us understand the stability of other sgRNAs. Another limitation our study is lack of unblinded data from the favipiravir study, precluding analysis by study arm. However, our findings of sgRNA persistence in clinical samples and lack of difference in its decline compared with gRNA are notable regardless of whether favipiravir reduced levels in one arm. For remdesivir, a RDRP inhibitor like favipiravir, we found no differential effect on sgRNA, compared with gRNA, in cell culture, despite effective reduction in viral replication and cytopathic effects.

322

In summary, we found that SARS-CoV-2 sgRNAs are persistently detectable in clinical samples, correlate strongly with gRNA, and decline at indistinguishable rates in clinical samples and cell culture. We find little evidence to support the premise that sgRNA detection is a reliable marker of transcriptionally active virus or that it provides additional information beyond detection of gRNA in clinical samples. We advise caution against using sgRNA assays to inform decisions concerning treatment or medical isolation.

### 330 Funding

331	This study was funded by Bill Gates and Melinda Gates Foundation (OPP1113682 - Stanford
332	Center for Human Systems Immunology). The parent clinical trials from which the clinical
333	samples were collected were supported by Stanford's Innovative Medicines Accelerator and by
334	Stanford ChEM-H.
335	
336	Acknowledgements
337	We thank the study teams and participants of the Lambda and favipiravir clinical trials. SARS-
338	Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281 was deposited by the CDC and
339	obtained through BEI Resources, NIAID, NIH. We thank Jaishree Garhyan, Director, Invitro
340	BSL-3 Service Center, Stanford School of Medicine.
341	
342	Author contributions
343	JRA and RV conceived the idea of the study. JRA, RV, GMC and CB designed the experiments.
344	PJ, HB, US, AS, MH, YM, and JRA enrolled the clinical cohorts. RV, EK, and GMC performed
345	the experiments. JRA, RV and EK analyzed data. RV and JRA wrote the first draft of the
346	manuscript, and all authors contributed to the final version.
347	
348	Conflicts of Interest
349	We declare that we have no conflicts of interest for this work.
350	
351	
352	
353	

#### 354 **References:**

- He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility
   of COVID-19. Nat Med. 2020 May;26(5):672-675.
- 357
  2. Kim MC, Cui C, Shin KR, et al. Duration of Culturable SARS-CoV-2 in Hospitalized
  358
  Patients with Covid-19. N Engl J Med. 2021 Feb 18;384(7):671-673.
- 359 3. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
   action patients with COVID-2019. Nature. 2020 May;581(7809):465-469
- 4. Mallett S, Allen AJ, Graziadio S, et al. At what times during infection is SARS-CoV-2
   detectable and no longer detectable using RT-PCR-based tests? A systematic review of
- 363 individual participant data. BMC Med. 2020 Nov 4;18(1):346.
- 364 5. Bullard J, Dust K, Funk D, Strong JE, et al. Predicting infectious SARS-CoV-2 from
  365 diagnostic samples. Clin Infect Dis. 2020 May 22:ciaa638.
- 366 6. COVID-19 Investigation Team. Clinical and virologic characteristics of the first 12
  367 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020
  368 Jun;26(6):861-868.
- 369
  7. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation
  370 with RT-PCR cycle threshold values in cases of COVID-19, England, January to May
  371 2020. Euro Surveill. 2020 Aug;25(32):2001483.
- 372 8. Jafari H, Amiri Gharaghani M. Cultural Challenges: The Most Important Challenge of
  373 COVID-19 Control Policies in Iran. Prehosp Disaster Med. 2020 Aug;35(4):470-471.
- Perera RAPM, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and Subgenomic
   RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg
   Infect Dis. 2020 Nov;26(11):2701-2704.

377	10. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus
378	macaques infected with SARS-CoV-2. Nature. 2020 Sep;585(7824):273-276.

- 37911. Sola I, Almazán F, Zúñiga S, Enjuanes L. Continuous and Discontinuous RNA Synthesis
- 380 in Coronaviruses. Annu Rev Virol. 2015 Nov;2(1):265-88.
- 381 12. Wu HY, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc
  382 Natl Acad Sci U S A. 2010 Jul 6;107(27):12257-62.
- 383 13. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 Vaccine against
   384 SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 Oct 15;383(16):1544-1555.
- 385 14. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents
   386 SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020 Oct;586(7830):578-582.
- 387 15. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs
  388 in diagnostic samples are not an indicator of active replication. Nat Commun. 2020 Nov
  389 27;11(1):6059.
- 390 16. Cliver DO. Capsid and Infectivity in Virus Detection. Food Environ Virol. 2009 Dec;1(3391 4):123-128.
- 392 17. Yin W, Luan X, Li Z, Zhou Z, Wang Q, Gao M, Wang X, Zhou F, Shi J, You E, Liu M,
  393 Wang Q, Jiang Y, Jiang H, Xiao G, Zhang L, Yu X, Zhang S, Eric Xu H. Structural basis
  394 for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol.
  395 2021 Mar;28(3):319-325.
- 396 18. Naydenova K, Muir KW, Wu LF, Zhang Z, Coscia F, Peet MJ, Castro-Hartmann P, Qian
- 397 P, Sader K, Dent K, Kimanius D, Sutherland JD, Löwe J, Barford D, Russo CJ. Structure
- 398 of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-
- 399 RTP. Proc Natl Acad Sci U S A. 2021 Feb 16;118(7)

- 400 19. Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, Farnung L,
- 401 Siewert A, Höbartner C, Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by
  402 remdesivir. Nat Commun. 2021 Jan 12;12(1):279.
- 403 20. <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html</u>
- 404 21. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of
- 405 outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat
  406 Commun. 2021 Mar 30;12(1):1967.
- 407 22. Klein S, Cortese M, Winter SL, et al. SARS-CoV-2 structure and replication
  408 characterized by in situ cryo-electron tomography. Nat Commun. 2020 Nov
  409 18:11(1):5885.
- 410 23. de Vries M, Mohamed AS, Prescott RA, et al. A comparative analysis of SARS-CoV-2
  411 antivirals characterizes 3CL<sup>pro</sup> inhibitor PF-00835231 as a potential new treatment for
  412 COVID-19. J Virol. 2021 Feb 23:JVI.01819-20.
- 413 24. R Core Team (2014). R: A language and environment for statistical computing. R
  414 Foundation for Statistical
- 415 Computing, Vienna, Austria. URL http://www.R-project.org/
- 416 25. Cenciarini-Borde C, Courtois S, La Scola B. Nucleic acids as viability markers for
  417 bacteria detection using molecular tools. Future Microbiol. 2009 Feb;4(1):45-64.
- 418 26. Nocker A, Camper AK. Novel approaches toward preferential detection of viable cells
  419 using nucleic acid amplification techniques. FEMS Microbiol Lett. 2009 Feb;291(2):137-
- 420 42.
- 421 27. NEIDHARDT FC, MAGASANIK B. Studies on the role of ribonucleic acid in the
  422 growth of bacteria. Biochim Biophys Acta. 1960 Jul 29;42:99-116.

423	28. Plantin J, Massanella M, Chomont N. Inducible HIV RNA transcription assays to
424	measure HIV persistence: pros and cons of a compromise. Retrovirology. 2018 Jan
425	17;15(1):9.

- 426 29. Escors D, Izeta A, Capiscol C, et al. Transmissible gastroenteritis coronavirus packaging
  427 signal is located at the 5' end of the virus genome. J Virol. 2003 Jul;77(14):7890-902.
- 30. Snijder EJ, Limpens RWAL, de Wilde AH, et al. A unifying structural and functional
  model of the coronavirus replication organelle: Tracking down RNA synthesis. PLoS
  Biol. 2020 Jun 8;18(6):e3000715.
- 431 31. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, et al. A molecular pore spans the
  432 double membrane of the coronavirus replication organelle. Science. 2020 Sep
  433 11;369(6509):1395-1398.
- 434 32. Wada M, Lokugamage KG, Nakagawa K, et al. Interplay between coronavirus, a
  435 cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. Proc Natl Acad
  436 Sci U S A. 2018 Oct 23;115(43):E10157-E10166.
- 437 33. Wu HY, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc
  438 Natl Acad Sci U S A. 2010 Jul 6;107(27):12257-62.
- 439 34. Perera RAPM, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and Subgenomic
  440 RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg
  441 Infect Dis. 2020 Nov;26(11):2701-2704.
- 442 35. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus
  443 macaques infected with SARS-CoV-2. Nature. 2020 Sep;585(7824):273-276.
- 444 36. Kim D, Lee JY, Yang JS, et al. The Architecture of SARS-CoV-2 Transcriptome. Cell.
  445 2020 May 14;181(4):914-921.e10.

446	37. Hogan CA, Huang C, Sahoo MK, et al. Strand-Specific Reverse Transcription PCR for
447	Detection of Replicating SARS-CoV-2. Emerg Infect Dis. 2021 Feb;27(2):632-635.
448	
449	
450	
451	
452	

#### 453 Figures

454

Figure 1: Correlation between genomic and subgenomic RNA in clinical samples. (A)
Genomic and sgRNA Ct values from clinical samples showed strong correlation (Pearson's r=
0.87). Dashed line reflects the diagonal of equal cycle thresholds, and solid line is the best fit
regression line with shaded area indicating the 95% confidence interval. (B) Detection of sgRNA
was predicted by cycle threshold value of gRNA.

day. Boxplot representing Ct values for genomic (Purple) and sgRNA (Blue) from serially
collected COVID-19 samples. (A) N-gene genomic and sgRNA decay trend in samples from the
Lambda trial collected at day 1, 4 and 6. (B) N-gene genomic and sgRNA decay trend in samples
from the favipiravir trial collected at day 1, 5 and 10.

Figure 2: Cycle threshold values for genomic and subgenomic RNA by sample collection

466

461

467 Figure 3: Proportion of samples positive for genomic and subgenomic RNA from time of 468 symptom onset. Samples from the Lambda and favipiravir trials were combined, and a positive 469 sample was one with cycle threshold <38. Error bars denote 95% exact binomial confidence 470 intervals.

Figure 4: SARS-CoV-2 genomic and subgenomic RNA kinetics in cell culture. SARS-CoV-2
genomic and sgRNA kinetics in A549<sup>ACE2+</sup> cells treated with 0.1% DMSO and 10µM remdesivir
(RDV). Solid lines indicate genomic (Purple) and sgRNA (Blue) levels in A549<sup>ACE2+</sup> cells
treated with remdesivir. Dotted lines indicate genomic (Purple) and sgRNA (Blue) levels in cells

476	treated with 0.1% DMSO. (A) Corresponds to genomic and sgRNA degradation kinetics in
477	washed cell pellets from A549 <sup>ACE2+</sup> cell line. (B) Corresponds to genomic and sgRNA
478	degradation kinetics in supernatant from A549 <sup>ACE2+</sup> cell line.

479

Supplementary Figure 1: (A) Sanger sequencing validation: SARS-CoV-2 sgRNA RT-PCR
results confirmed on Sanger sequencing. The samples were mapped to SARS-CoV-2 genome
(GenBank: MT568638.1) using MUSCLE (MUltiple Sequence Comparison by LogExpectation). Clinical samples assayed for sgRNA mapped to the leader sequence and N-gene.
(B) Schema on sgRNA synthesis in SARS-CoV-2. In full-length genomic RNA, the 5' terminal
contains a leader sequence (yellow). During viral transcription, leader sequence independently
fuses with different genes, resulting in smaller sgRNAs containing a common leader sequence.

487

Supplementary Figure 2: Boxplot representing Ct values for N-gene sgRNA (Blue) and E-gene sgRNA (Pink). Higher Ct values were observed for the E-gene sgRNA among the samples tested positive for N-gene sgRNA. A large fraction of samples 69% (24/35), which were positive for N-gene sgRNA were negative for E-gene sgRNA suggesting poor assay sensitivity.

492

493 **Supplementary Figure 3:** Cytopathic effect of SARS-CoV-2 on A549<sup>ACE2+</sup> cells treated with 494 either 10μM remdesivir or 0.1% DMSO. The images were collected using an EVOS XL core 495 imaging system (Thermo Fisher scientific), with a 10x objective, before collecting cell pellet and 496 supernatant from each treatment and time point. Cytopathic effect was characterized by 497 significant changes in morphology from well-spread epithelial cells to small rounded cells, the 498 inability to achieve confluency, and presence of excessive and unusual rounded floating cells, a

- 499 characteristic of cell death. (A) Remdesivir treated A549<sup>ACE2+</sup>cells 24hours after treatment at
- 500 48hpi (B) DMSO treated A549<sup>ACE2+</sup> cells 24hours after treatment at 48hpi (C) Remdesivir treated
- 501 A549<sup>ACE2+</sup> cells 48hours after treatment at 72hpi (D) DMSO treated A549<sup>ACE2+</sup> cells 48hours after
- 502 treatment at 72hpi (E) Remdesivir treated A549<sup>ACE2+</sup>cells 72hours after treatment at 96hpi (F)
- 503 DMSO treated A549<sup>ACE2+</sup> cells 72hours after treatment at 96hpi.

504

505

### 

### **Table 1: Characteristics of the study participants recruited from the Lambda and**

509 favipiravir trials.

	Lambda (n=66)	Favipiravir (n=139)	Overall (n=205)		
Age in years, median (IQR)	36 (31-48.5)	42 (33-53)	40 (32-52)		
Female, n (%)	28 (47.5%)	60 (46.2%)	88 (46.6%)		
Symptomatic at enrollment, n (%)	66 (100%)	131 (94.2%)	197 (96.1%)		
<b>Duration of symptoms prior to</b> <b>enrollment, days,</b> median (IQR)	5 (4-7.75)	5 (3-7)	5 (3-7)		
0-7 days, n (%)	49 (74.2%)	110 (79.1%)	159 (77.6%)		
8-14 days, n (%)	14 (21.2%)	20 (14.4%)	34 (16.6%)		
15-21 days, n (%)	3 (4.5%)	1 (0.7%)	4 (2.0%)		


### 512 Table 2: Genomic and sgRNA RT-qPCR positivity in longitudinal samples from the


### 513 Lambda and favipiravir trials.

	Day 1		Day 4	1	Day 6		
	Positive, n (%)	Median Ct	Positive (%)	Median Ct	Positive (%)	Median C	
gRNA	55/60 (91.6%)	24.4	50/55 (90.9%)	30.2	57/62 (91.9%)	33.2	
sgRNA	49/60 (81.6%)	26.9	41/55 (74.5%)	32.3	32/62(51.6%)	37.3	
		Longitudinal	swab samples from	m favipiravir	clinical trial (n=359	))	
	Day 1		Day	5	Ι	Day 10	
	Positive (%)	Median Ct	Positive (%)	Median Ct	Positive (%)	Median Ct	
gRNA	119/130 (91.5%)	23.8	102/123 (82.9%)	29.4	64/106 (60.3%)	34.4	
sgRNA	116/130 (89.2%)	25.4	95/123 (77.2%)	31.0	51/106 (49.5 %)	38	
		1 20			,		
Ct cutoff	value for positive	samples <38	3; Ct: cycle thres	hold	,		
Ct cutoff	Evalue for positive	samples <38	3; Ct: cycle thres	hold			
Ct cutoff	Evalue for positive	samples <38	3; Ct: cycle thres	hold			
Ct cutoff	value for positive	samples <38	3; Ct: cycle thres	hold			

- 522 Supplementary Table 1: RT-qPCR data on N-gene genomic and sgRNA degradation analysis in
- 523 remdesivir and DMSO-treated A549<sup>ACE2+</sup> cells. The cells were infected with SARS-CoV-2 at 24,
- 524 48hpi, 72hpi and 96hpi. Total number of copies per samples corresponding to Ct values were
- 525 calculated from standard curves using a standard curve derived from pET21b+ plasmids with the
- 526 target insert.
- 527
- 528


**(A)** 






**(A)** 

**(B)** 






## **(A)**


	gggtGCat	-ttcgaC	TGA-	ttTtG	gGgT(	ССАТТА	TCAGAO	ATTTT	AGTTT	GTTCgt	TTAGAGA	ACAGAT	С Т А С А А G А G А Т
	20 22 24 26	28 30 32 34	36 38	40 42	44 46 4	8 50 52	54 56 58	60 62 64	66 68 7	0 72 74	76 78 80 82	84 86 88	90 92 94 96 98 1
NCBI_SARS-CoV-2-N-gene_sgRNA	GGGTGCAT	- T T C G - C	TGA-	тттте	GGGT(	ССАТТА	TCAGAO	ATTTT	AGTTT	GTTCGT	TTAGAGA	ACAGAT	CTACAAGAGAT
Lambda_312-D6	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT(	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	TTAGAGA	ACAGAT	CTACAAGAGAT
Lambda_228-D1	GAGTGCAT	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	TTAGAGA	ACAGAT	СТАСААБАБАТ
Lambda_329-D1	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	ТТАСАСА	ACAGAT	СТАСААБАБАТ
Lambda_248-D1	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	АТТТТ	AGTTT	G T T C G T	ТТАБАБА	ACAGAT	СТАСААБАБАТ
LambdaR827 Preprint doi: https://doi.org/1	0. <mark>G G</mark> GO2 GOE 26.2	2 <mark>5751731C</mark> t6is-v€	sto G poste	eq April 290	2023. (The		dēr (Or4this Ar€	p¢int∏TTT	AGTTT	З Т Т С G Т	ТТАБАБА	ACAGAT	СТАСААБАБАТ
(which was not certified by peer r Lambda_306-D6	t is no author/f	under, who has and the raise	oranted m	nationalilie	ense to dis ense G T (	C A T T A	T C A G A C	Ĭ Ă T T T T	AGTTT	G T T C G T	T T A G A G A	ACAGAT	СТАСААБАБАТ
Favi_035-D1	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	G T T C G T	TTAGAGA	ACAGAT	C T A C A A G A G A T
Lambda_326-D1	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	АТТТТ	AGTTT	GTTCGT	ТТАСАСА	ACAGAT	СТАСААGАGАТ
Favi_013-D1	G G G T G C A T	- T T C G - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	TTAGAGA	ACAGAT	C T A C A A G A G A T
Favi_007-D1	G G G T G C A T	- <u>T T C G</u> - C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	TTAGAGA	ACAGAT	C T A C A A G A G A T
	ΝΝΑΤGϹΑΤ	- A T N G A C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	ТТАСАСА	ACAGAT	СТАСААБАБАТ
Lambda_337-D1	ΝΝΑΤGϹΑΤ	- N N C G A C	TGA-	тттте	GGGT	ССАТТА	TCAGAO	САТТТТ	AGTTT	GTTCGT	ТТАСАСА	ACAGAT	СТАСААБАБАТ
Favi_01-007	GAGTGCAN	АТТС Л А С	ΤGΑΝ	NNTNO	AGGT	ССАТТА	TCAGAO	ATTTT	AGTTT	GTTCGT	TTAGAGA	ACAGAT	СТАСААБАБАТ
Lambda_345-D4	GGGTGCAT	- T T C G - C	TGA-	TTTTG	GGGT	ССАТТА	TCAGAO	ATTTT	AGTTT	З Т Т С <mark>N</mark> Т	ТТАБАБА	ACAGAT	СТАСААБАБАТ
Lambda_339-D1	GNGNGCNN	- T T C G - C	TGA-	тттте	GGNT	ССАТТА	TCAGAO	ATTTT	AGTTT	GTTCGN	TTAGAGA	ACAGAT	СТАСААБАБАТ

SARS-CoV-2 N-gene


Leader sequence

**(B)** 






**(A)** 



medRxiv preprint doi: 100 medRxiv preprint d


(C)




10uM Remdesivir treated- A549ACE2+ cells infected with SARS-CoV-2




(D)



0.1% DMSO treated- A549ACE2+ cells infected with SARS-CoV-2





10uM Remdesivir treated- A549ACE2+ cells infected with SARS-CoV-2

0.1% DMSO treated- A549ACE2+ cells infected with SARS-CoV-2